While the block deal removed a long-standing overhang on the stock, brokerages remain divided on Biocon’s outlook, with Bernstein maintaining a cautious stance and DAM Capital turning more optimistic.
While the block deal removed a long-standing overhang on the stock, brokerages remain divided on Biocon’s outlook, with Bernstein maintaining a cautious stance and DAM Capital turning more optimistic.